Epigenomics' First-Half '09 Revenues Rise 37 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today reported that its first-half 2009 revenues increased 37 percent, due to income from licensing agreements, and its net loss fell 14 percent year over year.

The German molecular diagnostics developer said that it had first-half revenues of €2.1 million ($3 million), compared to first-half 2008 revenues of €1.5 million. The firm said that its revenue came from R&D payments, licensing fees, reimbursements, and product sales from its research-use-only kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.